Compare Boston Scientific Corporation (BSX) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs ProShares UltraPro QQQ ETF — how do they compare? Boston Scientific Corporation trades at $51.58 (market cap $74.19B), while ProShares UltraPro QQQ ETF trades at $74.76. The key difference: ProShares UltraPro QQQ ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | TQQQ | |
|---|---|---|
Market Cap | $74.19B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $108.14 | $87.22 |
52-Week Low | $42.63 | $37.89 |
Enterprise Value | $86.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.
The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.
TQQQ trades at $74.61, up 1.12% with a bullish technical signal from moving averages. The leveraged ETF benefits from strong Nasdaq-100 performance and AI-driven tech momentum. Recent institutional buying by Bay Colony Advisory Group and positive earnings from hyperscalers support current levels. However, the RSI at 74 suggests potential overbought conditions near key resistance at $75.
Outlook remains positive given tech sector strength, but volatility decay and leverage risks require careful position sizing. The ETF's structural costs compound daily, making it better suited for tactical rather than long-term holdings. Current momentum favors continued upside if tech earnings maintain strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
